



Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research

March 23, 2015

DUBLIN--(BUSINESS WIRE)--Mar. 23, 2015-- [Alkermes plc](#) (NASDAQ: ALKS) today announced that clinical data on aripiprazole lauroxil, an investigational, novel, long-acting injectable atypical antipsychotic for the treatment of schizophrenia, and ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia, are scheduled to be presented at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs, Colo., March 28-April 1, 2015.

Key poster presentations include:

Sunday, March 29, 2015, 12:00 – 2:00 p.m. MDT

Poster 90: "Effects of Aripiprazole Lauroxil on Agitation and Hostility in Patients with Schizophrenia" will be presented by Leslie Citrome, M.D., MPH, Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College.

Poster 142: "A Phase 2, Randomized, Olanzapine-Controlled Study of the Safety, Tolerability and Efficacy of ALKS 3831 in Adults with Schizophrenia" will be presented by Bernard Silverman, M.D., Vice President, Clinical Science and Drug Safety, Alkermes, Inc.

Poster 145: "Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles, and Related Safety Considerations in Acute Schizophrenia" will be presented by Henry Nasrallah, M.D., Chair, Department of Neurology and Psychiatry at Saint Louis University School of Medicine.

Poster 146: "Efficacy and Safety of Aripiprazole Lauroxil in Patients Experiencing Severe Psychotic Symptoms During an Acute Exacerbation of Schizophrenia" will be presented by Steven Potkin, M.D., Director of Clinical Research and Professor of Psychiatry, Psychiatry & Human Behavior at the University of California Irvine School of Medicine.

Poster 147: "Effect of Aripiprazole Lauroxil on Personal and Social Functioning and Health-Related Quality of Life Among Patients with Schizophrenia" will be presented by Peter Weiden, M.D., Professor of Psychiatry at the University of Illinois Medical Center.

A full list of all Alkermes posters being presented at the ICOSR meeting is available at <http://www.schizophreniacongress.org/>.

About Aripiprazole Lauroxil

Aripiprazole lauroxil is an injectable atypical antipsychotic with one-month and extended-duration formulations in development for the treatment of schizophrenia. Once in the body, aripiprazole lauroxil converts to aripiprazole, which is commercially available under the name ABILIFY®. As a long-acting investigational medication based on Alkermes' proprietary LinkeRx® technology, aripiprazole lauroxil is designed to have multiple dosing options and to be administered in a ready-to-use, pre-filled product format.

About ALKS 3831

ALKS 3831 is a proprietary, investigational medicine designed as a broad-spectrum antipsychotic for the treatment of schizophrenia. ALKS 3831 is composed of samidorphan, a novel, potent mu-opioid antagonist, in combination with the established antipsychotic drug, olanzapine. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, in patients with schizophrenia and to have utility in the treatment of schizophrenia in patients with alcohol use.

About Alkermes

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the therapeutic value of aripiprazole lauroxil and ALKS 3831. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond the company's control, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties include, among others, whether preclinical and clinical results for ALKS 3831 will be predictive of future clinical study results; whether ALKS 3831 or aripiprazole lauroxil could be shown to be unsafe or ineffective; and those risks described in the Alkermes plc Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2014, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release.

LinkeRx® is a registered trademark of Alkermes Pharma Ireland Limited Corporation. ABILIFY® is a registered trademark of Otsuka Pharmaceutical

Co., Ltd.

Source: Alkermes plc

Alkermes Contacts:

For Investors:

Rebecca Peterson, +1 781-609-6378

or

For Media:

Jennifer Snyder, +1 781-609-6166